Krystal Biotech Statistics
Total Valuation
Krystal Biotech has a market cap or net worth of $9.63 billion. The enterprise value is $8.54 billion.
| Market Cap | 9.63B |
| Enterprise Value | 8.54B |
Important Dates
The next estimated earnings date is Monday, November 2, 2026, before market open.
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Krystal Biotech has 29.60 million shares outstanding. The number of shares has increased by 1.46% in one year.
| Current Share Class | 29.60M |
| Shares Outstanding | 29.60M |
| Shares Change (YoY) | +1.46% |
| Shares Change (QoQ) | +0.49% |
| Owned by Insiders (%) | 9.94% |
| Owned by Institutions (%) | 92.06% |
| Float | 23.62M |
Valuation Ratios
The trailing PE ratio is 40.85 and the forward PE ratio is 40.46. Krystal Biotech's PEG ratio is 0.92.
| PE Ratio | 40.85 |
| Forward PE | 40.46 |
| PS Ratio | 21.87 |
| Forward PS | 17.11 |
| PB Ratio | 7.09 |
| P/TBV Ratio | 7.09 |
| P/FCF Ratio | 37.37 |
| P/OCF Ratio | 35.37 |
| PEG Ratio | 0.92 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 42.84, with an EV/FCF ratio of 33.12.
| EV / Earnings | 35.36 |
| EV / Sales | 19.38 |
| EV / EBITDA | 42.84 |
| EV / EBIT | 43.18 |
| EV / FCF | 33.12 |
Financial Position
The company has a current ratio of 8.32, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.32 |
| Quick Ratio | 7.73 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.04 |
| Debt / FCF | 0.03 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 20.12% and return on invested capital (ROIC) is 40.16%.
| Return on Equity (ROE) | 20.12% |
| Return on Assets (ROA) | 9.37% |
| Return on Invested Capital (ROIC) | 40.16% |
| Return on Capital Employed (ROCE) | 14.40% |
| Weighted Average Cost of Capital (WACC) | 6.98% |
| Revenue Per Employee | $1.49M |
| Profits Per Employee | $818,522 |
| Employee Count | 295 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 0.62 |
Taxes
| Income Tax | -14.84M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +71.07% in the last 52 weeks. The beta is 0.50, so Krystal Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | +71.07% |
| 50-Day Moving Average | 339.53 |
| 200-Day Moving Average | 306.23 |
| Relative Strength Index (RSI) | 45.61 |
| Average Volume (20 Days) | 261,944 |
Short Selling Information
The latest short interest is 3.48 million, so 11.74% of the outstanding shares have been sold short.
| Short Interest | 3.48M |
| Short Previous Month | 3.16M |
| Short % of Shares Out | 11.74% |
| Short % of Float | 14.72% |
| Short Ratio (days to cover) | 12.53 |
Income Statement
In the last 12 months, Krystal Biotech had revenue of $440.48 million and earned $241.46 million in profits. Earnings per share was $7.97.
| Revenue | 440.48M |
| Gross Profit | 416.87M |
| Operating Income | 197.75M |
| Pretax Income | 226.62M |
| Net Income | 241.46M |
| EBITDA | 199.29M |
| EBIT | 197.75M |
| Earnings Per Share (EPS) | $7.97 |
Balance Sheet
The company has $845.63 million in cash and $8.85 million in debt, with a net cash position of $1.09 billion or $36.96 per share.
| Cash & Cash Equivalents | 845.63M |
| Total Debt | 8.85M |
| Net Cash | 1.09B |
| Net Cash Per Share | $36.96 |
| Equity (Book Value) | 1.36B |
| Book Value Per Share | 45.92 |
| Working Capital | 932.25M |
Cash Flow
In the last 12 months, operating cash flow was $272.34 million and capital expenditures -$14.56 million, giving a free cash flow of $257.78 million.
| Operating Cash Flow | 272.34M |
| Capital Expenditures | -14.56M |
| Depreciation & Amortization | 1.54M |
| Net Borrowing | n/a |
| Free Cash Flow | 257.78M |
| FCF Per Share | $8.71 |
Margins
Gross margin is 94.64%, with operating and profit margins of 44.89% and 54.82%.
| Gross Margin | 94.64% |
| Operating Margin | 44.89% |
| Pretax Margin | 51.45% |
| Profit Margin | 54.82% |
| EBITDA Margin | 45.24% |
| EBIT Margin | 44.89% |
| FCF Margin | 58.52% |
Dividends & Yields
Krystal Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.46% |
| Shareholder Yield | -1.46% |
| Earnings Yield | 2.51% |
| FCF Yield | 2.68% |
Analyst Forecast
The average price target for Krystal Biotech is $395.44, which is 21.52% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $395.44 |
| Price Target Difference | 21.52% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 31.66% |
| EPS Growth Forecast (3Y) | 24.06% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Krystal Biotech has an Altman Z-Score of 30.07 and a Piotroski F-Score of 5.
| Altman Z-Score | 30.07 |
| Piotroski F-Score | 5 |